Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15518216 | 0.86 | MAPT (0.38) | MAPTTP53PLATPOLBCSNK2A1 | |
| SCHEMBL15518062 | 0.79 | MAPT (0.44) | MAPTTP53PLATCSNK2A1GAA | |
| SCHEMBL15519153 | 0.74 | MAPT (0.46) | MAPTTP53PLATPOLBCSNK2A1 | |
| SCHEMBL2122792 | 0.74 | TBK1 (0.40) | MAPTGAAALDH1A1 | |
| SCHEMBL15518354 | 0.74 | MAPT (0.58) | MAPTPOLBCSNK2A1LPAR1ALDH1A1 | |
| SCHEMBL2125438 | 0.73 | KDR (0.41) | POLBLPAR1ALDH1A1 | |
| SCHEMBL15518351 | 0.73 | MAPT (0.57) | MAPTTP53POLBCSNK2A1LPAR1 | |
| SCHEMBL15518388 | 0.73 | MAPT (0.47) | MAPTCSNK2A1MEN1KMT2A | |
| SCHEMBL15518353 | 0.73 | MAPT (0.49) | MAPTTP53POLBCSNK2A1LPAR1 | |
| SCHEMBL15518108 | 0.73 | MAPT (0.49) | MAPTPOLBCSNK2A1LPAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169215-B2 | LPAR—substituted cyanopyrazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150218106-A1 | LPAR - SUBSTITUTED CYANOPYRAZOLE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-08-06 | — | — | US | disclosed |
| EP-2892882-A1 | LPAR - SUBSTITUTED CYANOPYRAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037303-A1 | LPAR - SUBSTITUTED CYANOPYRAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218106-A1 | LPAR - SUBSTITUTED CYANOPYRAZOLE COMPOUNDS | LPAR3, LPAR1, LPAR2 | MAPT 4773/4885TP53 4152/4885PLAT 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.